Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Ategenos, a pharmatech company, today announced that Co-Founder and Chief Executive Officer Don DeGolyer is leading the ...

A judge has advanced OxyContin maker Purdue Pharma's $7 billion-plus plan to settle thousands of lawsuits over the toll of opioids.

In this regard, we highlight three generic drugmakers — Sandoz, Teva Pharmaceuticals and Viatris — which are well-positioned to navigate these headwinds due to their global scale, diversified ...

TME Pharma Announces New Strategy Diede van den Ouden, an experienced CEO with successful background in small-cap turnarounds, to be nominated for appointment as CEO at upcoming AGM in June 2025 ...

The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and would not solve ...

Dr. Reddy's, Sandoz and Teva Pharmaceuticals have been highlighted in this Industry Outlook article.

The Trump administration has taken its next steps toward imposing more tariffs on key imports, launching investigations into imports of computer chips and products that contain them, chip making ...

Global drugmakers’ stocks dropped across the board today after U.S. President Donald Trump reiterated plans for a “major” tariff on pharmaceutical imports, threatening an interwoven supply ...